Acute Porphyria Drug Database

B01AA04 - Phenprocoumon
Propably not porphyrinogenic
PNP

Rationale
Phenprocoumon is metabolized by CYP 2C9, 3A4 and 2C8, but induction or inhibition of the CYP enzymes are not observed or suspected.
Chemical description
Phenprocoumon is a coumarin derivate.
Therapeutic characteristics
Phenprocoumon is a vitamin K antagonist that acts as a long acting oral anticoagulant. It is administered orally and has a half- life of 5-9 days (Ufer 2004).
Metabolism and pharmacokinetics
In vitro, CYP2C9 and CYP3A4 is found to be the main catalyzing enzymes of the R-enantiomer of phenprocoumon hydroxylation while CYP 2C8 has part in the hydroxylation of the S-enantiomer (Ufer 2004, 2005). No CYP relevant drug-drug interaction with phenprocoumon as a perpetrator has been reported in the literature (Drugbank, Lexi-Interact, Micromedex, SPC).

References

  1. Scientific articles
  2. Ufer M, Svensson JO et al. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol. 2004 May;60(3):173-82. PMID 15054565. #1154
  3. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44(12):1227-46. PMID 16372822. #1155
  4. Drug reference publications
  5. DrugBank. Phenprocoumon. #1151
  6. Drug interaction databases
  7. Lexi-Interact, via UpToDate. #1152
  8. Micromedex® 2.0 (online). Drug Interactions). (24.05.2017). #1153

Similar drugs
Explore alternative drugs in similar therapeutic classes B01A / B01AA or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙